AMG 108
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- AMG 108
- Accession Number
- DB05545
- Description
AMG 108 was investigated for use as an antirheumatic agent.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies Purchasing individual compounds or compound libraries for your research?
Learn More- Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- AMG 108
- AMG-108
Pharmacology
- Indication
Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with AMG 108. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with AMG 108. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with AMG 108. Alirocumab The risk or severity of adverse effects can be increased when AMG 108 is combined with Alirocumab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when AMG 108 is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when AMG 108 is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with AMG 108. Asfotase alfa The risk or severity of adverse effects can be increased when AMG 108 is combined with Asfotase alfa. Atezolizumab The risk or severity of adverse effects can be increased when AMG 108 is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when AMG 108 is combined with Atoltivimab. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 877879-38-4
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Osteoarthritis (OA) 1 2 Completed Treatment Rheumatoid Arthritis 2 2 Withdrawn Prevention Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created on November 18, 2007 11:25 / Updated on June 12, 2020 10:52
